Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BioLineRx Ltd. Capital/Financing Update 2017

Mar 30, 2017

6692_rns_2017-03-30_3419f9cb-51a0-4601-9140-cb32a6daa03b.htm

Capital/Financing Update

Open in viewer

Opens in your device viewer

_________ false

������� �� ��� ��"� 2 381
BIOLINE RX LTD
Corporation no: 513398750 9253
- - -
Israel Securities Authority Tel Aviv Stock Exchange C003 ( Public ) Reported via MAGNA: 30/03/2017
www.isa.gov.il www.tase.co.il Reference: 2017-02-028861 Time of broadcast: 23:44 23:43:16

Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000 The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on Preliminary Prospectus Supplement

Prelim_pro-supp_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM Date of revision of form structure: 06/03/2017
Address: HaMa'ayan 2 , Modi'in 7177871   , Israel Tel: 08-6429100 , Fax: 08-6429101
E-mail address: [email protected]   Company site: www.biolinerx.com
Previous names of reporting entity:
Name of the Signatory: Kotler Norman Harold Position of Signatory in the reporting corporation: General Counsel & Company Secretary Name of Employer Company:
Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: [email protected] 1
Israel